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Endometriosis is characterized by the presence of endometrial tissues outside the uterus. It affects fe-
males in their reproductive years, and may be an estrogen-dependent condition. The estimated preva-
lence of endometriosis in the general population is as high as 10%, and is increased in females with
subfertility. The diagnosis of endometriosis is usually suspected clinically and conﬁrmed by transvaginal
ultrasound or magnetic resonance imaging of the pelvis. The gold standard of diagnosis is surgical visual
inspection of the pelvic organs by an experienced surgeon during laparoscopy. A positive histology will
conﬁrm the diagnosis; however, a negative histology does not exclude it. Serum cancer antigen-125
levels may be increased in women with endometriosis, however, it is a poor diagnostic tool in com-
parison to laparoscopy. The management of endometriosis is dependent on whether the primary
problem is pain or subfertility. The primary objectives of an intervention include removing endometriotic
implants, removing nodules or cysts, restoring normal anatomy, reducing disease progression, and
providing symptomatic relief. Treatment must be individualized and take into consideration the impact
of the condition on quality of life. This may require a multidisciplinary approach that involves a pain
clinic and counseling services.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometriosis is a debilitating condition that is characterized by
the presence of endometrial tissue outside the uterus. It affects
females in their reproductive years and it is believed to be an
estrogen-dependent condition.1 Some females with endometriosis
are asymptomatic. However, it impacts the physical, mental, and
social well-being of many women. The estimated prevalence of
endometriosis in the general population is as high as 10%,2 and is
increased in females with infertility.2 Endometriosis is associated
with infertility, although it commonly presents with the symptom
of pain in the form of dysmenorrhea, dyspareunia, and pelvic
pain.3,4 Other symptoms include dyschezia in patients with bowel
involvement,4,5 or dysuria in patients with bladder involvement.4,6
The precise pathogenesis of endometriosis is unclear, however,
this disease may occur because of the dissemination of they Unit, GOG Ofﬁce, 3rd Floor,
9899, Singapore.
-Stekly).
for Gynecologic Endoscopy and Minimendometrium to ectopic sites and the resulting establishment of
deposits of ectopic endometrium.7 There are three distinct forms of
endometriosis: (1) endometriotic implants on the surface of pelvic
peritoneum and ovaries (i.e., peritoneal endometriosis); (2) ovarian
cysts lined by endometrioid mucosa (i.e., endometrioma); and (3) a
solid mass comprising endometriotic tissue mixed with adipose
and ﬁbromuscular tissue between the rectum and vagina (i.e.,
rectovaginal endometriotic nodule).8
This article aimed to review the current diagnostic methods and
management of endometriosis. This review only covers the man-
agement of endometriosis-associated pain. The management of
endometriosis-associated infertility is a larger topic and requires a
separate review.Diagnosis
The diagnosis of suspected endometriosis is based on the clin-
ical history of symptoms, clinical examination, and imaging tech-
niques. A deﬁnitive diagnosis of endometriosis can only be
determined by the histology of lesions removed at surgery; how-
ever, a negative histology does not exclude the diagnosis.9ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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tients present with dysmenorrhea, noncyclical pelvic pain, deep
dyspareunia, infertility, fatigue, dyschezia, dysuria, hematuria, or
rectal bleeding.4 A clinical examination should be performed in all
patients suspected of having endometriosis. Deeply inﬁltrating
nodules are most reliably detected when clinical examination is
performed during menstruation.9 The ﬁndings of a ﬁxed retro-
verted uterus, pelvic tenderness, tender uterosacral ligaments, or
adnexal masses support a diagnosis of endometriosis.4,9 The diag-
nosis of endometriosis is more apparent if deeply inﬁltrating
nodules are palpated on the rectovaginal wall or visible in the
posterior vaginal fornix during clinical examination.4,9,10
The gold standard test for diagnosing endometriosis is visual
inspection of the pelvis during laparoscopy.4,9 Clinicians should
conﬁrm a positive laparoscopy by histology, especially in women
undergoing surgery for an ovarian endometrioma and/or deep
inﬁltrating disease so as to identify endometriosis and exclude
malignancy.4,9
Transvaginal sonography is useful for diagnosing or excluding
ovarian endometriomas. However, this technique has limited value
for diagnosing peritoneal endometriosis.11 In women with signs
and symptoms of bowel endometriosis, transvaginal sonography is
useful for identifying or ruling out rectal endometriosis.12 Trans-
rectal sonography should be considered with or without barium
enema studies to map the extent of bowel wall involvement in
women with deep endometriosis. However, it is not possible to
conclude to what degree a preoperative barium enema, trans-
vaginal sonography, or transrectal sonography is accurate in the
diagnosis of bowel wall involvement in women with deep endo-
metriosis.13 There is insufﬁcient evidence to support magnetic
resonance imaging (MRI) as a useful test to diagnose peritoneal
endometriosis. However, MRI may be beneﬁcial for establishing the
extent of the disease in women with deep endometriosis.14
The level of cancer antigen (CA)-125 may be raised in women
with endometriosis. However, CA-125 levels in plasma, urine, or
serum should not be used to diagnose endometriosis because it has
limited potential with a low sensitivity of 28% and a speciﬁcity of
90%.4,9,15,16 May and colleagues17 performed a systematic review to
assess the clinical signiﬁcance of all proposed immunological bio-
markers for endometriosis in the serum, plasma and urine, how-
ever, none has been clearly shown to be of clinical use.17 May and
colleagues15 subsequently performed another systematic review to
assess the clinical value of markers derived from endometrial tis-
sue, menstrual ﬂuid, or uterine ﬂuid to diagnose endometriosis
noninvasively. They concluded that no marker could conclusively
be used to diagnose endometriosis. However, several studies
identiﬁed endometrial nerve ﬁbers and molecules involved in cell-
cycle control, cell adhesion, and angiogenesis as promising options
for future biomarker research.
Management of endometriosis-associated pain
Medical treatment
Endometriosis-associated pain includes dysmenorrhea, dys-
pareunia, dysuria, dyschezia, and chronic pelvic pain. Empirical
treatment of symptoms presumably caused by endometriosis
without a prior deﬁnitive diagnosis should include detailed coun-
seling and a trial of adequate analgesia, progestogens, or combined
oral contraceptive pills.4,9 Empirical treatment is advocated
because of the invasiveness of laparoscopy and the ease of pre-
scribing these drugs. However, other causes of pelvic pain symp-
toms should be excluded before starting an empirical treatment.
The effectiveness of nonsteroidal anti-inﬂammatory drugs
(NSAIDs) in treating endometriosis-associated pain is not wellestablished because of the lack of studies.4,9 However, there is
sufﬁcient evidence to support that NSAIDs effectively treat primary
dysmenorrhea.18 Therefore, clinicians should consider NSAIDs or
other analgesic drugs to reduce endometriosis-associated pain,
after discussing with women the adverse effects commonly asso-
ciated with the frequent use of these medications.
Hormonal treatment to suppress ovarian function for 6 months
reduces endometriosis-associated pain.9 In a Cochrane review,19
only one study was found that included the use of hormonal con-
traceptives in the treatment of pain in women with endometriosis.
The evidence is limited, although oral contraceptive pills are
commonly used to treat endometriosis-associated pain; they can
also serve as contraception, regulate the menstrual cycle, and have
a long-term safety proﬁle.
Brown et al20 concluded in their Cochrane review that sufﬁcient
evidence exists to support the effectiveness of progestogens in
reducing pain in women with endometriosis. This group of drugs
includes medroxyprogesterone acetate, dienogest, cyproterone
acetate, norethisterone acetate, or danazol. Clinicians should
consider the adverse effect proﬁles of these medications and tailor
treatment to improve the quality of life of a woman. In this respect,
danazol should not be used as a ﬁrst-line drug if there are other
medical treatments available because it has severe adverse effects
such as acne, weight gain, vaginal spotting, muscle cramps, and
irreversible voice change.
Dienogest (Visanne; Bayer Healthcare, Berlin, Germany) is a
synthetic oral progestin with strong progestational and moderate
anti-gonadotrophic effects, however, it has no androgenic, gluco-
corticoid, or mineralocorticoid activity. A randomized clinical trial
indicated that oral dienogest is more effective than a placebo in
reducing pelvic pain in patients with a diagnosis of endometri-
osis.21 In clinical trials that compared oral dienogest with
gonadotropin-releasing hormone (GnRH) agonists for 16 weeks or
24 weeks in women with endometriosis,22 dienogest was equally
effective in reducing pelvic pain, compared with GnRH agonists.
Dienogest has fewer hypoestrogenic adverse effects and hence little
effect on the bone mineral density; however, it has been associated
with a higher incidence of abnormal menstrual bleeding patterns,
which usually settles after 90 days of treatment duration and is
generally well tolerated by patients.23
The antiprogestogen gestrinone is an effective therapy for
treating painful symptoms associated with endometriosis. Ges-
trinone was studied in four randomized controlled trials and
proven to reduce pelvic pain, dysmenorrhea, deep dyspareunia, and
nonmenstrual pain.20 In one study, gestrinone resulted in severe
androgenic adverse effects (e.g., acne, oily skin, voice change, hair
loss) and several patients withdrew from the study. Hence, women
should be counseled about its adverse effects before starting this
treatment.
Petta and colleagues24 compared the levonorgestrel-releasing
intrauterine system (LNG-IUS) with monthly leuprolide acetate in
a randomized, controlled multicenter study that involved 83 pa-
tients with endometriosis. After 6 months of treatment, both
groups had signiﬁcantly reduced visual analogue pain scores,
however, no difference existed between the groups. Gomes et al25
and Ferreira et al26 used a similar regimen, as described previ-
ously, and found a signiﬁcant reduction in pelvic pain scores after 6
months of treatment; however, there was no intergroup difference
in either study. With these data, it can be concluded that the LNG-
IUS appears to reduce endometriosis-associated pain and has a
potential beneﬁt because of a better adverse effect proﬁle.
In a Cochrane review by Brown et al,27 a GnRH agonist wasmore
effective than a placebodbut inferior to the LNG-IUS and dana-
zoldin relieving endometriosis-associated pain. In addition, GnRH
agonist has a worse adverse effect proﬁle in all reviewed studies.27
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clinicians should prescribe hormonal add-back therapy (i.e., the
combination of low dose estrogen and progestogen or tibolone)
with the start of the GnRH agonist therapy to prevent bone loss and
hypoestrogenic symptoms.28e30 However, because of the lack of
large randomized controlled trials, it remains unclear which type of
add-back therapy should be used. Because of the severe adverse
effects of GnRH agonists, women should be counseled in detail
before starting this treatment.
Aromatase inhibitors have been studied as a treatment for
endometriosis-associated pain in premenopausal women. The au-
thors of two systematic reviews concluded that, in women with
pain from rectovaginal endometriosis that is refractory to other
medical or surgical treatment, aromatase inhibitors can be used in
combination with oral contraceptive pills, progestogens, or GnRH
agonists because they reduce endometriosis-associated pain.31,32
However, aromatase inhibitors should only be prescribed after
patients have had detailed counseling because of their severe
adverse effect proﬁle (e.g., vaginal dryness, hot ﬂashes, decreased
bone mineral density) and lack of evidence on their long-term
effects.
Surgical treatment
In recent decades, laparoscopy has dominated over open sur-
gery in the management of endometriosis. This includes elimina-
tion of endometriotic lesions via excision, diathermy, or ablation,
division of adhesions to restore pelvic anatomy, and interruption of
the pelvic nerve pathways to improve pain control.
Crosignani et al33 showed in a nonrandomized study that lap-
aroscopy and laparotomy were equally effective in the treatment of
chronic pelvic pain related to endometriosis. However, laparoscopy
is associated with less pain, shorter hospital stay, quicker recovery,
and better cosmesis; therefore, it is preferred to laparotomy. The
Cochrane review by Jacobson et al34 showed signiﬁcant beneﬁts of
therapeutic laparoscopy at 6 months and 12 months after surgery.
In the ﬁve included randomized controlled trials, the methods of
treatment included excision, coagulation, or laser vaporization of
endometriotic lesions.34 The reviewers recommend that clinicians
should surgically treat lesions when endometriosis is identiﬁed at
laparoscopy because this treatment effectively reduces
endometriosis-associated pain.
Peritoneal endometriosis
In peritoneal endometriosis, ablation and excision are equally
effective in reducing endometriosis-associated pain.35,36 However,
this conclusion is derived from one small study and a larger study
with suboptimal design. Hence, this ﬁnding should be treated with
caution.
Ovarian endometrioma
Hart et al37 reviewed two randomized controlled trials that
compared laparoscopic excision of ovarian endometriotic cysts
(3 cm) with drainage and coagulation by bipolar diathermy. Both
studies revealed a lower recurrence of dysmenorrhea and dyspar-
eunia after cystectomy, compared with drainage and coagulation
only. In addition, the rate of cyst recurrence was lower with the
excisional approach.
Carmona et al38 compared cystectomy with carbon dioxide
(CO2) laser vaporization, and found the recurrence of cysts were
more common at 12 months after laser vaporization (but not at 60
months). The time to recurrence was also shorter postlaser vapor-
ization in comparison with cystectomy.38 Hence, it can be
concluded that cystectomy is superior to drainage and coagulation
or CO2 laser vaporization with regard to the recurrence ofendometriosis-related pain and recurrence of endometriotic cysts.
However, it is apt to counsel females that the risk of ovarian failure
after bilateral ovarian endometrioma removal is reportedly 2.4% in
the literature.39
Ovarian endometriomas per semay damage ovarian reserve, and
cystectomy of endometriomas may cause greater damage to the
ovarian reserve in comparisonwith other benign ovarian cysts. The
risk factors associated with surgery-related decline in ovarian
reserve include whether the endometriomas were bilateral and
size of cyst (greater risk exists for cysts >7 cm). The preoperative
serum anti-Mullerian hormone level and age were not risk factors
associated with surgery-related decline in ovarian reserve.40
Deep endometriosis
Surgical removal of deep endometriosis via excision can be
advocated because it reduces endometriosis-associated pain and
improves the quality of life.41,42 However, this procedure is asso-
ciated with signiﬁcant complication rates, especially if it involves
the bowel. Deep endometriosis extends beneath the peritoneum
and may involve the uterosacral ligaments, pelvic adverse walls,
rectovaginal septum, vagina, bowel, bladder, or ureter. Surgical
treatment of bowel endometriosis includes superﬁcial shaving,
discoid resection, and segmental resection of the bowel to remove
the deep endometriosis nodules. Surgical treatment of bladder
endometriosis involves excision of the lesion and primary closure
of the bladder wall. Ureteral endometriosis lesions may be excised
after stenting the ureter; however, in the presence of intrinsic le-
sions or signiﬁcant obstruction, segmental excision with end-to-
end anastomosis or reimplantation may be required.
As the last resort to treat endometriosis-associated pain, clini-
cians should consider hysterectomy with removal of the ovaries
and all visible endometriotic nodules in women who have
completed their family and failed to respond to more conservative
treatments.4
The effectiveness of surgical interruption of pelvic nerve path-
ways to reduce dysmenorrhea was reviewed by Proctor and col-
leagues43 in a Cochrane review that included six randomized
controlled trials; three trials evaluated the beneﬁt of laparoscopic
uterosacral nerve ablation (LUNA) in addition to conservative
laparoscopic surgery for endometriosis and the remaining three
studies evaluated the effects of presacral neurectomy (PSN) in
addition to conservative surgery for endometriosis. The reviewers
concluded that LUNA should not be performed as an additional
procedure with conservative surgery because it has not been
shown to be effective in reducing endometriosis-associated pain.
By contrast, PSN is effective as an additional procedure to conser-
vative surgery to reduce endometriosis-associated midline pain;
however, it is associated with an increased risk of bleeding and
bowel and urinary symptoms.
Furness et al44 in their Cochrane review concluded that there
was no evidence to support the use of preoperative hormonal
treatment to improve the outcome of surgery for pain in women
with endometriosis. There was similarly no proven beneﬁt of
postoperative hormonal treatment within 6 months after surgery
because it does not improve the outcome of surgery for pain.
However, for patients not desiring to become pregnant after
endometriosis surgery, secondary prevention of dysmenorrhea can
be achieved by the postoperative use of a LNG-IUS or by long-term
combined oral contraceptives for at least 18e24 months.45,46
Nonmedical treatments
The European Society of Human Reproduction and Embryology
(ESHRE) guidelines do not recommend the use of complementary
or alternative medicine in the treatment of endometriosis-
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are not well established.4 These treatments include neuro-
modulators, nerve blocks, transcutaneous electrical nerve stimu-
lation, acupuncture, behavioral therapy, nutritional supplements,
reﬂexology, homeopathy, traditional Chinese medicine, herbal
medicine, sports and exercise. However, the ESHRE Guideline
Development Group acknowledges that women with endometri-
osis who seek complementary and alternative medicine to treat
their pain symptoms may beneﬁt from it.
Conclusion
To summarize, the primary objectives of interventions include
the removal of endometriotic implants, nodules, or cysts, restora-
tion of normal anatomy, reduction of disease progression and
symptomatic relief. Treatment must be individualized, and take
into consideration the impact of the condition on the quality of life.
This may require a multidisciplinary approach that involves treat-
ment at a pain clinic and counseling services.
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